1.Shajan, B. et al. Functional implications of the C182F TAAR1 variant identified in patients with schizophrenia. Genomic Psychiatry2, 42–48 (2026). https://doi.org/10.61373/gp026r.0006
2.Nair, P. C., Shajan, B. & Bastiampillai, T. Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs. Molecular Psychiatry29, 1925–1928 (2024). https://doi.org/10.1038/s41380-024-02466-z
3.Shajan, B. et al. Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations. Human Genomics18, 61 (2024). https://doi.org/10.1186/s40246-024-00620-w
4.Shajan, B., Bastiampillai, T., Hellyer, S. D. & Nair, P. C. Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment. Frontiers in Psychiatry15 (2024). https://doi.org/10.3389/fpsyt.2024.1464550
5.Shajan, B., Bastiampillai, T. & Nair, P. C. The association between trace amine-associated receptor 1 (TAAR1) genetic mutations and neuropsychiatric disorders. Genomic Psychiatry1, 17–20 (2024). https://doi.org/10.61373/gp024v.0058
6.Tibrewal, P. et al. Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum? Molecular Psychiatry28, 1839–1842 (2023).
7.Nair, P. C. et al. Trace amine-associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities. ACS Pharmacology & Translational Science5, 183–188 (2022).
8.Nair, P. C. et al. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Molecular Psychiatry27, 88–94 (2022).
9.Nair, P. C., McKinnon, R. A., Miners, J. O. & Bastiampillai, T. Binding of clozapine to the GABAB receptor: clinical and structural insights. Molecular Psychiatry25, 1910–1919 (2020).